Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael D. Tarantino, MD, Nichola Cooper, Donald Beam, Jenny M. Despotovic, DO, Alexey A. Maschan, MD, Kejia Wang, PhD, Melissa Jeanne Eisen, MD, Charles Bowers, MD

Blood (2019) 134 (Supplement_1): 1095.

https://doi.org/10.1182/blood-2019-131241

Published: 2019

Journal Articles

Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study

Rachael F. Grace, MD, D. Mark Layton, MB BS, FRCP, FRCPCH, Frédéric Galactéros, MD PhD, Wilma Barcellini, MD, Eduard J. van Beers, MD PhD, Hassan M. Yaish, MD, Yaddanapudi Ravindranath, MBBS, Kevin H. M. Kuo, MDMSc,FRCPC, Sujit Sheth, MD, Janet L. Kwiatkowski, MD MSCE, Lei Hua, PhD, Peter F. Hawkins, PhD, Chris Mix, MD, Bertil Glader, MD PhD

Blood (2019) 134 (Supplement_1): 3512.

https://doi.org/10.1182/blood-2019-123406

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2018-99-116225

Published: 2018

Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 448.

https://doi.org/10.1182/blood-2018-99-111692

Published: 2018

Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD

Blood (2018) 132 (Supplement 1): 1186.

https://doi.org/10.1182/blood-2018-99-115792

Published: 2018

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Oliver Meyer, James B. Bussel, MD, Raymond S Wong, MBChB, MD, Abderrahim Khelif, Miona Stankovic, Joan Maier, Mansoor N. Saleh

Blood (2018) 132 (Supplement 1): 1152.

https://doi.org/10.1182/blood-2018-99-114694

Published: 2018

Journal Articles

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Jerzy Windyga, Oleksandra Stasyshyn, MD PhD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2018-99-111295

Published: 2018

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Blood (2018) 132 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2018-99-112478

Published: 2018

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Shinichi Makita, MD, PhD, Takashi Ishida, MD PhD, Shigeru Kusumoto, MD, Kenji Ishitsuka, MD PhD, Makoto Yoshimitsu, MD PhD, Yoshitaka Imaizumi, MD PhD, Yasushi Sawayama, MD, PhD, Shogo Takeuchi, MD, Atae Utsunomiya, MD, PhD, Kunihiro Tsukasaki, MD PhD, Sumiaki Fujitani, MSc, Kazushi Araki, D.V.M., PhD

Blood (2017) 130 (Supplement 1): 4070.

https://doi.org/10.1182/blood.V130.Suppl_1.4070.4070

Published: 2017

Journal Articles

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Haifa Kathrin Al-Ali, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, PhD MD, Anna Marina Liberati, Philipp Le Coutre, Carmen Garcia-Hernandez, Andrey Zaritskey, Renato Tavares, Martin Griesshammer, Vikas Gupta, MD PhD, Pia Raanani, Pilar Giraldo, PhD, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Francesco Mannelli, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4204.

https://doi.org/10.1182/blood.V130.Suppl_1.4204.4204

Published: 2017

Journal Articles

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Veronique Leblond, Guy Cantin, MD, Agostino Cortelezzi, Prof, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, MD, Andrey Zaritskey, Jean-Louis Merot, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Stephan Stilgenbauer, MD PhD, Robin Foà, Francesc Bosch

Blood (2017) 130 (Supplement 1): 3015.

https://doi.org/10.1182/blood.V130.Suppl_1.3015.3015

Published: 2017

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Torben Plesner, MD, Hendrik-Tobias Arkenau, Francesca Marianatal Gay, Monique C Minnema, Mario Boccadoro, Philippe Moreau, MDPhD, James D Cavenagh, Aurore Perrot, MD, Jacob Laubach, MD, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan Schecter, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 1828.

https://doi.org/10.1182/blood.V130.Suppl_1.1828.1828

Published: 2017

Journal Articles

Pivotal Trial with Intravenous Plasminogen Replacement in Patients with Plasminogen Deficiency Demonstrates Long-Term Efficacy for Treatment and Prevention of Ligneous Lesions

Charles T Nakar, MD, Joseph M Parker, MD, Neelam Thakral, Brandon M. Hardesty, MD, Gary Albert, Pierre Laurin, MSc, BPharm, John Moran, MD, Per Morten Sandset, MD PhD, Amy D. Shapiro, MD

Blood (2017) 130 (Supplement 1): 84.

https://doi.org/10.1182/blood.V130.Suppl_1.84.84

Published: 2017

Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo

Blood (2017) 130 (Supplement 1): 434.

https://doi.org/10.1182/blood.V130.Suppl_1.434.434

Published: 2017

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, James B. Bussel, MD, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, MD PhD, Nancy Carpenter, Melissa Eisen, Bhakti Mehta

Blood (2016) 128 (22): 869.

https://doi.org/10.1182/blood.V128.22.869.869

Published: 2016

Journal Articles

Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial

Manuel Carcao, Carmen Altisent, PhD, Giancarlo Castaman, Katsuyuki Fukutake, MD PhD, Aida Inbal, MD, Bryce A. Kerlin, Craig M. Kessler, MD, Riitta Lassila, MD PhD, Johannes Oldenburg, Prof, Anders Rosholm, May-Lill Garly, MD PhD, Diane J. Nugent, MD

Blood (2016) 128 (22): 2573.

https://doi.org/10.1182/blood.V128.22.2573.2573

Published: 2016

Journal Articles

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Lynda Foltz, MD FRCP, Giuseppe A. Palumbo, MD, Bruno Martino, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Anna Marina Liberati, MD, Philipp D. Le Coutre, MD, Alessandro M. Vannucchi, MD, Carmen Garcia-Hernandez, MD, Renato Tavares, MD, Martin Griesshammer, MD, Vikas Gupta, MD, Pia Raanani, MD, Pilar Giraldo, MD PhD, Catherine Bouard, Julian Perez Ronco, MD MBA, Sadhvi Khanna, MS, Andrey Zaritskey, MD

Blood (2016) 128 (22): 3107.

https://doi.org/10.1182/blood.V128.22.3107.3107

Published: 2016

Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 479.

https://doi.org/10.1182/blood.V126.23.479.479

Published: 2015

NARROW

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Pivotal Trial with Intravenous Plasminogen Replacement in Patients with Plasminogen Deficiency Demonstrates Long-Term Efficacy for Treatment and Prevention of Ligneous Lesions

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only